SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Julian who wrote (971)7/28/2000 12:40:26 PM
From: Garth Richmond   of 1321
 
EU Commission Approves Visudyne For The Treatment of Wet AMD in the European Union

"Visudyne therapy is the first approved drug treatment for this devastating condition. Now with approval throughout the European Union, Visudyne will provide new hope to many of the approximately 200,000 patients in the European Union who lose their vision from wet AMD every year," said Luzi von Bidder, President of CIBA Vision's worldwide Ophthalmics
Business Unit. "This much needed therapy will be available to eye care professionals and their patients across the European Union within the next few weeks."

biz.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News